1999-2020年美国酒精相关死亡性别趋势
该横断面时间序列研究使用美国CDC WONDER数据库1999-2020年酒精相关死亡数据,共识别605 948例酒精归因死亡,总年龄调整死亡率(AAMR)为8.3/10万(95%CI 8.3-8.3)。男性死亡风险为女性的2.88倍(95%CI 2.86-2.89)。但近年两性酒精相关死亡均上升,2018-2020年男性AAMR年增12.5%(95%CI 6.4%-19.1%),女性年增14.7%(95%CI 9.1%-20.5%)。年龄、种族/民族、死因和地区亚组趋势存在差异。作者认为需要进一步研究理解相关因素,并针对女性酒精使用制定靶向干预和循证治疗。
要点
- 1999-2020年美国共识别605 948例酒精归因死亡,总AAMR为8.3/10万(95%CI 8.3-8.3)。
- 男性酒精相关死亡风险为女性的2.88倍(95%CI 2.86-2.89)。
- 2018-2020年男性AAMR年增12.5%(95%CI 6.4%-19.1%),女性年增14.7%(95%CI 9.1%-20.5%)。
- 近年女性酒精相关死亡增长率高于男性,但男性绝对死亡负担仍更高。
- 年龄、种族/民族、死因和地区亚组间趋势存在差异。
适用人群与场景
- 美国1999-2020年酒精相关死亡人群,按性别、种族/民族、年龄和人口普查地区亚组分析。
诊断标准与关键阈值
- 酒精相关死亡依据国际疾病分类第十版(ICD-10)根本死因编码识别,包括酒精相关中毒、肝病、胃炎、心肌病、肌病、多神经病和假性库欣综合征等。
研究设计与关键结果
- 研究类型为横断面时间序列研究,使用美国CDC WONDER数据库1999-2020年酒精相关死亡数据,共605 948例酒精归因死亡。
- 总AAMR为8.3/10万(95%CI 8.3-8.3)。
- 男性死亡风险为女性的2.88倍(95%CI 2.86-2.89)。
- 2018-2020年男性AAMR年增12.5%(95%CI 6.4%-19.1%),女性年增14.7%(95%CI 9.1%-20.5%)。
- 年龄、种族/民族、死因和地区亚组趋势存在差异。
证据类型、等级与局限
- 证据类型:横断面时间序列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为需要进一步研究理解与女性酒精相关死亡增长率更高相关的具体因素。
- 作者认为针对女性酒精使用的靶向干预和循证治疗对于有效应对酒精相关死亡增加是必要的。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Alcohol consumption rates have been increasing among women in the US, which may affect mortality rates and sex gaps. Therefore, conducting a comprehensive assessment of sex differences in alcohol-related deaths is essential to inform targeted interventions and policies aimed at reducing the burden of alcohol-related harm among the population.
OBJECTIVE: To examine sex differences in the burden and trends of alcohol-related mortality in the US from 1999 to 2020.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional time series study used Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research data on alcohol-related deaths from 1999 to 2020. Alcohol-related deaths were identified from the underlying cause of death files using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, codes, including alcohol-related poisoning, liver disease, gastritis, cardiomyopathy, myopathy, polyneuropathy, and pseudo-Cushing syndrome, among others.
MAIN OUTCOMES AND MEASURES: Age-adjusted mortality rates (AAMRs) were analyzed by sex and substratified by race and ethnicity, age, and census region. Rate ratios and 95% CIs calculated by Taylor series were used to assess sex differences in mortality burden. Joinpoint regression was used to assess temporal trends.
RESULTS: A total of 605 948 alcohol-attributed deaths were identified in the US from 1999 through 2020 (AAMR, 8.3 per 100 000 persons; 95% CI, 8.3-8.3 per 100 000 persons). The mortality burden was higher among male individuals than female individuals, with male individuals being 2.88 (95% CI, 2.86-2.89) times more likely to die compared with female individuals. However, temporal trends showed an increase in alcohol-related deaths for both male and female individuals in recent years, with higher rates of increase among female individuals relative to male individuals. The AAMR increased by 12.5% (95% CI, 6.4%-19.1%) per year among male individuals from 2018 to 2020 but increased by 14.7% (95% CI, 9.1%-20.5%) per year among female individuals during the same period. Trend differences were observed across subtypes of age, race and ethnicity, cause, and region.
CONCLUSIONS AND RELEVANCE: This study of alcohol-related mortality in the US suggests there has been a significantly higher rate of increase in deaths among female individuals in recent years. These findings underscore the need for further research to understand the specific factors associated with this trend. The development of targeted interventions and evidence-based treatments for alcohol use among female individuals becomes imperative in effectively addressing the increasing rates of alcohol-related deaths.
参考来源
- Karaye IM, Maleki N, Hassan N, et al. Trends in Alcohol-Related Deaths by Sex in the US, 1999-2020. JAMA Netw Open. 2023. PMID: 37505494. doi:10.1001/jamanetworkopen.2023.26346
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。